The trial is conducted in Asia, Europe and North America. The aim of the study is to evaluate the safety of administration under the skin of turoctocog alfa pegol (SC N8-GP) in patients with severe haemophilia A.

Inclusion Criteria:

• Male, age above or equal to 18 years at the time of signing informed consent,(part A).
• Male, age above or equal to 12 years at the time of signing informed consent,(part B).
• Diagnosis of congenital haemophilia A based on medical records (FVIII activity <1%).
• History of more than 150 exposure days to any FVIII containing products.

Exclusion Criteria:

• Previous participation in this trial. Participation is defined as signed informed consent.

(Patients who have completed part A are allowed to also participate in part B. If so, a separate informed consent covering part B must be signed.)

• Immune compromised patients due to human immunodeficiency virus (HIV) infection (defined as viral load greater than or equal to 400.000 copies/mL and/or cluster of differentiation 4+ (CD4+) lymphocyte count less than or equal to 200/μL performed at screening or defined by medical records no older than 6 months)
• Any history of FVIII inhibitors (defined by medical records within 8 years of randomisation)
• Inhibitors to FVIII (greater than or equal to 0.6 Bethesda unit (BU)) at screening, measured by Nijmegen modified Bethesda method at central laboratory.

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com